Creating cancer treatments based on protein kinase inhibitors (PKI) – one of the most important pharmaceutical classes of compounds frequently used in drugs for cancer treatments. Read more »

The XSpray HyNap™ is a PLATFORM TECHNOLOGY that can improve the solubility and bio-availability of even the most challenging drug substances such as PKI’s.
LEARN MORE ABOUT THE TECHNOLOGY

At XSpray we specialize in the formulation of protein kinase inhibitors, many of which suffer from formulation related medical problems.

Reducing - PH Dependant Absorption

Minimizing – Food effect

Improving – Limited solubility

Minimizing – Drug-drug interactions

Reducing – Highly variable bioavailability

CEO's comment

What's happening?

  • Press / Published November 8, 2016

    XSpray’s new share issue oversubscribed

    Stockholm, Sweden, November 8, 2016 – XSpray Microparticles AB, a clinical stage product development company that creates improved and generic versions of existing cancer products, today announced the successful completion of a new share issue of SEK 41 million.

    “I’m pleased with the strong interest from both existing and more than 70 new investors. The proceeds from this share issue will allow us to continue to progress our lead product candidate, XS-004, further in clinical development with the goal to achieve next relevant clinical milestone during the first half of 2017 as well as expanding our internal product pipeline with new high value product candidates, “says Per Andersson, CEO of XSpray.

    For further information, please contact:
    Per Andersson, CEO, XSpray Microparticles AB
    Tel: +46-706-88 23 48, e-mail: per.andersson@xspray.com

    TO EDITORS

    About XSpray
    XSpray is a clinical stage product development company creating improved and generic versions of already marketed drugs within the field of cancer treatment. XSpray applies its patent protected technology platform to generate a pipeline of anti-cancer products with clinically relevant improvements to patients or high value generic versions. Two of XSpray’s product candidates are currently in clinical development. Its lead product candidate, XS-004, is designed as an improved version of a marketed product for the treatment of leukemia selling for more than BUSD 1,5 annually. For further information, please visit www.xspray.com

    About HyNapTM
    XSpray has developed a hybrid nanoparticle technology (HyNapTM) – a proprietary patent protected technology platform that enables and improves cancer treatments based on protein kinase inhibitors (PKI’s). Improvements have been made in more than half of the 30 currently marketed PKI’s, whereof many have already been proven in animals and in clinical trials. For further information, please visit www.xspray.com

    About protein kinase inhibitors (PKI’s)
    Protein kinase inhibitors (PKI’s) are a breakthrough group of compounds, remarkably effective in treating a wide range of cancers. However, they often have limitations such as variable bioavailability due to poor solubility and pH-dependent absorption. These together with a possible food interaction can lead to poor therapeutic effect and sometimes fatal outcome. About 20% of the total cancer pharmaceutical value are presently from PKIs. Total expected sales value for 2020 is more than BUSD 20.

    news2
  • Press / Published October 2, 2015

    XSpray Microparticles receives 18 million SEK investment

    STOCKHOLM – October 2, 2015  The 18 million SEK investment will be used to finance the clinical development of XSpray’s lead compound, XS-004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS-004 is based on a well-known protein kinase inhibitor (PKI) compound.

    Press release Recipharm – Xspray 151002 web

    news2